Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/06/2010US20100113610 Methods for controlling inflammatory and immunological diseases
05/06/2010US20100113609 Methods and compositions for malaria prophylaxis
05/06/2010US20100113608 Tryptase Enzyme Inhibiting Aminothiophenols
05/06/2010US20100113607 Pharmaceutical Compositions
05/06/2010US20100113606 Aminopropanol modulators of beta-1 adrenergic receptor
05/06/2010US20100113604 Combination therapies for the treatment of obesity
05/06/2010US20100113603 Combination therapies for the treatment of obesity
05/06/2010US20100113602 Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
05/06/2010US20100113601 Method for decreasing sebum production
05/06/2010US20100113600 Anti-cancer agents and androgen inhibition activity compound
05/06/2010US20100113599 Amphipathic carboxylates for the treatment of immune-related disorders
05/06/2010US20100113598 High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
05/06/2010US20100113597 Pharmaceutical composition for prevention of progress of intestinal constriction associated with crohn's disease
05/06/2010US20100113596 Method for inhibiting liver fibrosis via retinoic acid derivative
05/06/2010US20100113595 Treatment of neurodegenerative conditions
05/06/2010US20100113593 Topical fungicidal agents for treating nail disorders
05/06/2010US20100113592 Unsymmetrical aromatic ether diacids and absorbable polymers therefrom
05/06/2010US20100113591 Methods and compositions for treating amyloid-related diseases
05/06/2010US20100113590 Adam inhibitor
05/06/2010US20100113589 Deuterated darunavir
05/06/2010US20100113588 Composition and Methods for the Protection of Hair From Treated Pool Water
05/06/2010US20100113587 use of abscissic acid to treat various diseases, including neurodegenerative and neuromuscular diseases
05/06/2010US20100113586 Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
05/06/2010US20100113585 Compositions and methods for treating cancer
05/06/2010US20100113584 Novel use of (-)-epigallocatechin gallate
05/06/2010US20100113583 Combination therapies for the treatment of obesity
05/06/2010US20100113582 Methods and compositions for treating hiv infections
05/06/2010US20100113581 Combination therapies for the treatment of obesity
05/06/2010US20100113580 Combination therapies for the treatment of obesity
05/06/2010US20100113579 Prodrugs of excitatory amino acids
05/06/2010US20100113578 Prevention of and countermeasures against mitochondrial disease
05/06/2010US20100113577 Isolated nucleic acid molecules corresponding to micro rna 145 (mirna-145) and their use in treating colon cancer
05/06/2010US20100113576 Device and Method for Processing or Treating Surfaces By Means of A Dry Ice Granulate
05/06/2010US20100113575 Method for detecting autoprocessed, secreted pcsk9
05/06/2010US20100113574 Polynucleotides for enhancing expression of a polynucleotide of interest
05/06/2010US20100113573 Modulation of hif1 beta expression
05/06/2010US20100113572 Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof
05/06/2010US20100113571 Compounds having anti-adhesive effects on cancer cells
05/06/2010US20100113570 Prevention and treatment of post-operative cognitive dysfunction
05/06/2010US20100113569 Isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells
05/06/2010US20100113568 Methods for binding lewis y antigen
05/06/2010US20100113567 Recombinant VSV For The Treatment of Tumor Cells
05/06/2010US20100113566 Nucleic acid for treatment or prevention of immunodeficiency virus infection
05/06/2010US20100113565 Immunostimulatory combinations and methods
05/06/2010US20100113564 Chemically synthesized nucleic acid molecule; nucleic acids with a pyrimidine modification; inflammatory, respiratory, pulmonary, autoimmune, cardiovascular, neurodegenerative, and/or proliferative and cancerous diseases, traits, or conditions
05/06/2010US20100113563 Method for Treating Pain with a Calmodulin Inhibitor
05/06/2010US20100113562 Therapeutic targets and molecules
05/06/2010US20100113561 Microrna molecules
05/06/2010US20100113560 Compositions and methods for treating hematopoietic malignancies
05/06/2010US20100113558 Compounds and methods
05/06/2010US20100113557 Method for prevention of tumor
05/06/2010US20100113556 Novel crystal forms of pyrrolylheptanoic acid derivatives
05/06/2010US20100113555 Modulators of ATP-Binding Cassette Transporters
05/06/2010US20100113554 Manufacture and products thereof of photosensitizing nanomaterials and their use in photodynamic treatment
05/06/2010US20100113553 Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom
05/06/2010US20100113551 Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
05/06/2010US20100113550 New Crystal Forms
05/06/2010US20100113549 Pyrrolidine compounds
05/06/2010US20100113548 Antagonists of bitter taste receptors and uses thereof
05/06/2010US20100113547 Novel imidazolidine compounds as androgen receptor modulators
05/06/2010US20100113546 Imidazol-4-one and Imidazole-4-thione Compounds
05/06/2010US20100113545 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
05/06/2010US20100113544 Suppressant for cerebral infarction attributed to long-time ischemia
05/06/2010US20100113542 Triazole derivative as an hsp 90 inhibitor
05/06/2010US20100113541 Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
05/06/2010US20100113540 Azole and Thiazole Derivatives and Their Use
05/06/2010US20100113539 Compounds for treating ophthalmic diseases and disorders
05/06/2010US20100113538 N-hydroxy-4- benzamidine 2 ethansulfonic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same
05/06/2010US20100113536 haloalkylsulfone substituted compounds useful for treating obesity and diabetes
05/06/2010US20100113535 Treatment of presbyopia with alpha- picolinic acid and its analogs
05/06/2010US20100113534 Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same
05/06/2010US20100113533 Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide
05/06/2010US20100113532 MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
05/06/2010US20100113531 Thiazolidine derivatives as orexin receptor antagonists
05/06/2010US20100113530 S1p lyase inhibitors for the treatment of cerebral malaria
05/06/2010US20100113529 Dosage regimen for comt inhibitors
05/06/2010US20100113528 Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
05/06/2010US20100113527 Crystalline forms of dexlansoprazole
05/06/2010US20100113526 Process for the Preparation of Esomeprazole Magnesium Dihydrate
05/06/2010US20100113524 Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
05/06/2010US20100113523 Tryptase Enzyme Inhibiting Aminopyridines
05/06/2010US20100113522 COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY
05/06/2010US20100113521 Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
05/06/2010US20100113520 Kinase knockdown via electrophilically enhanced inhibitors
05/06/2010US20100113519 1,5-Dideoxy-1,5-imino-D-glucitol Compounds
05/06/2010US20100113518 Methods of using anti-inflammatory compounds
05/06/2010US20100113517 Method for the treatment of fabry disease using pharmacological chaperones
05/06/2010US20100113516 Quinolynylmethylimidizoles as therapeutic agents
05/06/2010US20100113515 Pten inhibitor or maxi-k channels opener
05/06/2010US20100113514 Fused heterocyclic compounds as ion channel modulators
05/06/2010US20100113512 Method of treatment using novel antagonists or inverse agonists at opioid receptors
05/06/2010US20100113511 Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors
05/06/2010US20100113510 Quinuclidinol derivatives as muscarinic receptor antagonists
05/06/2010US20100113509 Modulators of cystic fibrosis transmembrane conductance regulator
05/06/2010US20100113508 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
05/06/2010US20100113507 3-Tetrazolyl Indazoles, 3-Tetrazolyl Pyrazolopyridines, and use Thereof
05/06/2010US20100113506 Composition for preventing or treating thrombus- or embolus- associated disease
05/06/2010US20100113505 Amino-naphthyridine derivatives
05/06/2010US20100113504 Amide compounds and their use as antitumor agents
05/06/2010US20100113503 Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors